Podcast 42: CDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023 

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industry’s radar.

Key topics: (see Chapter Markers in drop down menu in audio player above) 

  • Baxter (1:26)
  • Samsung Biologics (3:10)
  • Lotte Biologics (4:37)
  • Fujifilm Diosynth Biotechnologies (6:44)
  • Lonza (9:09)
  • WuXi Biologics (11:14)
  • Bachem (14:15)
  • Agilent Technologies (15:36)
  • WuXi STA (16:12)
  • CordenPharma (17:21)
  • eureKING (18:50)
  • NewBiologix (20:43)
  • Ascend Gene & Cell Therapies (21:38)

Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show